Ardelyx share price today

(ARDX)

Ardelyx share price is $5.22 & ₹442.45 as on 14 Dec 2024, 2.30 'hrs' IST

$5.22

▲

-0.02

(-0.38%)

Market is closed - opens 8 PM, 16 Dec 2024

View live Ardelyx share price in Dollar and Rupees. Guide to invest in Ardelyx from India. Also see the sentimental analysis on Indian investors investing in Ardelyx. Get details on the Indian mutual funds that are investing in Ardelyx. Get Analyst recommendations and forecasts along with all the Ardelyx's financials.

Ardelyx share price movements

$5.13
$5.31
$5.22
1.72%
Downside
Day's Volatility :3.39%
Upside
1.69%
$4.34
$10.13
$5.22
16.85%
Downside
52 Weeks Volatility :57.15%
Upside
48.47%

Ardelyx Returns

Period	Ardelyx Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-16.08%	-9.7%	0.0%
6 Months	-17.01%	-3.3%	0.0%
1 Year	-11.68%	4.2%	0.0%
3 Years	335.0%	4.2%	-18.1%

Ardelyx Key Statistics

in dollars & INR

Previous Close	$5.24
Open	$5.24
Today's High	$5.31
Today's Low	$5.13
Market Capitalization	$1.3B
Today's Volume	$2.1M
52 Week High	$10.13
52 Week Low	$4.3405
Revenue TTM	$251.8M
EBITDA	$-62.2M
Earnings Per Share (EPS)	$-0.32
Profit Margin	-28.82%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-41.54%

How to invest in Ardelyx from India?

It is very easy for Indian residents to invest directly in Ardelyx from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ardelyx stock in both rupees (INR) and dollars (USD). Search for Ardelyx or ARDX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ardelyx or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ardelyx shares which would translate to 0.162 fractional shares of Ardelyx as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Ardelyx

-46.15%

Period: Sep 14, 2024 to Dec 13, 2024. Change in 30 Days versus previous period

Investment in Ardelyx from India has reduced in the last 30 days as on Dec 14, 2024. -46.15% less purchase transactions for Ardelyx in the last 30 days versus the previous period.

68%

Period: Sep 14, 2024 to Dec 13, 2024. Change in 30 Days versus previous period

Search volume for Ardelyx on INDmoney from India has grown in the last 30 days as on Dec 14, 2024. 68% more investors are searching Ardelyx in the last 30 days versus the previous period.

Global Institutional Holdings in Ardelyx

HHG PLC
9.09%
BlackRock Inc
7.41%
Vanguard Group Inc
5.74%
State Street Corp
5.13%
Macquarie Group Ltd
3.78%
Eventide Asset Management, LLC
3.13%

Analyst Recommendation on Ardelyx

Buy

93%Buy

6%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Ardelyx(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ardelyx

What analysts predicted

Upside of 106.47%

Current:

$5.22

Target:

$10.78

Insights on Ardelyx

Price Movement
In the last 3 years, ARDX stock has moved up by 322.6%
Increasing Revenue
Revenue is up for the last 4 quarters, 34.36M → 98.24M (in $), with an average increase of 29.3% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -28.80M → -809.0K (in $), with an average increase of 667.9% per quarter
ARDX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 31.5% return, outperforming this stock by 41.2%
Price to Sales
ForARDX every $1 of sales, investors are willing to pay $4.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Ardelyx Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$2.6M	↓ 93.79%
Net Income	$-91.3M	↑ 41.9%
Net Profit Margin	-3.5K%	↓ 3348.84%

	FY19	Y/Y Change
Revenue	$5.3M	↑ 102.57%
Net Income	$-94.9M	↑ 3.99%
Net Profit Margin	-1.8K%	↑ 1704.26%

	FY20	Y/Y Change
Revenue	$7.6M	↑ 43.36%
Net Income	$-94.3M	↓ 0.66%
Net Profit Margin	-1.2K%	↑ 552.06%

	FY21	Y/Y Change
Revenue	$10.1M	↑ 33.36%
Net Income	$-158.2M	↑ 67.7%
Net Profit Margin	-1.6K%	↓ 320.75%

	FY22	Y/Y Change
Revenue	$52.2M	↑ 416.57%
Net Income	$-67.2M	↓ 57.51%
Net Profit Margin	-128.85%	↑ 1437.61%

	FY23	Y/Y Change
Revenue	$124.5M	↑ 138.61%
Net Income	$-66.1M	↓ 1.7%
Net Profit Margin	-53.08%	↑ 75.77%

	Q2 FY23	Q/Q Change
Revenue	$22.3M	↑ 96.44%
Net Income	$-17.1M	↓ 36.05%
Net Profit Margin	-76.66%	↑ 158.83%

	Q3 FY23	Q/Q Change
Revenue	$56.4M	↑ 152.5%
Net Income	$6.6M	↓ 138.72%
Net Profit Margin	11.76%	↑ 88.42%

	Q4 FY23	Q/Q Change
Revenue	$34.4M	↓ 39.06%
Net Income	$-28.8M	↓ 534.48%
Net Profit Margin	-83.82%	↓ 95.58%

	Q1 FY24	Q/Q Change
Revenue	$46.0M	↑ 33.93%
Net Income	$-26.5M	↓ 7.93%
Net Profit Margin	-57.62%	↑ 26.2%

	Q2 FY24	Q/Q Change
Revenue	$73.2M	↑ 59.1%
Net Income	$-16.5M	↓ 37.95%
Net Profit Margin	-22.47%	↑ 35.15%

	Q3 FY24	Q/Q Change
Revenue	$98.2M	↑ 34.17%
Net Income	$-809.0K	↓ 95.08%
Net Profit Margin	-0.82%	↑ 21.65%

	FY18	Y/Y Change
Profit	$2.1M	↓ 93.63%

	FY19	Y/Y Change
Profit	$4.7M	↑ 118.64%

	FY20	Y/Y Change
Profit	$7.4M	↑ 58.64%

	FY21	Y/Y Change
Profit	$9.1M	↑ 22.5%

	FY22	Y/Y Change
Profit	$48.0M	↑ 428.1%

	FY23	Y/Y Change
Profit	$106.7M	↑ 122.02%

	Q2 FY23	Q/Q Change
Profit	$18.8M	↑ 91.66%

	Q3 FY23	Q/Q Change
Profit	$49.3M	↑ 161.85%

	Q4 FY23	Q/Q Change
Profit	$29.3M	↓ 40.65%

	Q1 FY24	Q/Q Change
Profit	$38.5M	↑ 31.33%

	Q2 FY24	Q/Q Change
Profit	$63.2M	↑ 64.37%

	Q3 FY24	Q/Q Change
Profit	$82.5M	↑ 30.52%

	FY18	Y/Y Change
Operating Cash Flow	$-70.3M	↑ 7.8%
Investing Cash Flow	$-29.9M	↓ 145.79%
Financing Cash Flow	$103.6M	↑ 15017.23%

	FY19	Y/Y Change
Operating Cash Flow	$-76.5M	↑ 8.84%
Investing Cash Flow	$23.4M	↓ 178.19%
Financing Cash Flow	$155.5M	↑ 50.14%

	FY20	Y/Y Change
Operating Cash Flow	$-81.4M	↑ 6.47%
Investing Cash Flow	$-31.4M	↓ 234.52%
Financing Cash Flow	$22.8M	↓ 85.35%

	FY21	Y/Y Change
Operating Cash Flow	$-152.6M	↑ 87.33%
Investing Cash Flow	$50.9M	↓ 262.04%
Financing Cash Flow	$83.0M	↑ 264.41%

	FY22	Y/Y Change
Operating Cash Flow	$-70.0M	↓ 54.08%
Investing Cash Flow	$18.4M	↓ 63.86%
Financing Cash Flow	$75.3M	↓ 9.23%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-14.7M	↓ 67.1%
Investing Cash Flow	$-59.2M	↑ 505.57%
Financing Cash Flow	$11.5M	↓ 77.39%

Ardelyx Technicals Summary

Sell

Neutral

Buy

Ardelyx is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ardelyx Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ardelyx Inc	10.83%	-17.01%	-11.68%	335.0%	-31.32%
Regeneron Pharmaceuticals, Inc.	-6.54%	-30.04%	-14.88%	11.15%	94.49%
Biontech Se	16.24%	36.11%	17.79%	-58.06%	243.94%
Alnylam Pharmaceuticals, Inc.	-4.84%	56.03%	32.5%	28.46%	104.33%
Vertex Pharmaceuticals Incorporated	-4.18%	-2.1%	12.92%	119.64%	111.27%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ardelyx Inc	NA	NA	-0.08	-0.19	-0.42	-0.12	NA	0.67
Regeneron Pharmaceuticals, Inc.	19.12	19.12	1.15	45.03	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ardelyx Inc	Buy	$1.3B	-31.32%	NA	-28.82%
Regeneron Pharmaceuticals, Inc.	Buy	$84.9B	94.49%	19.12	33.61%
Biontech Se	Buy	$28.9B	243.94%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.8B	104.33%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	111.27%	32.84	-4.51%

About Ardelyx

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.

Organization	Ardelyx
Employees	267
CEO	Mr. Michael G. Raab
Industry	Health Technology

Management People of Ardelyx

Name	Title
Mr. Michael G. Raab	President, CEO & Director
Ms. Elizabeth A. Grammer Esq.	Chief Legal & Administrative Officer and Secretary
Dr. Laura A. Williams M.D., M.P.H.	Chief Medical Officer
Mr. Justin A. Renz CPA, MBA	Chief Financial & Operations Officer
Mr. Joseph Reilly	Senior VP of Finance & Principal Accounting Officer
Ms. Caitlin Lowie	Vice President of Corporate Communications & Investor Relations
Mr. Mike Kelliher	Executive Vice President of Corporate Development & Strategy
Ms. Charon Spencer Sr.	Chief Human Resources Officer
Mr. David P. Rosenbaum	Chief Development Officer
Mr. Robert C. Blanks	Chief Regulatory Affairs & Quality Assurance Officer

Important FAQs about investing in Ardelyx from India :

What is Ardelyx share price today?

Ardelyx share price today stands at $5.22, Open: $5.24 ; Previous Close: $5.24 ; High: $5.31 ; Low: $5.13 ; 52 Week High: $10.13 ; 52 Week Low: $4.34. The stock opens at $5.24, after a previous close of $5.24. The stock reached a daily high of $5.31 and a low of $5.13, with a 52-week high of $10.13 and a 52-week low of $4.34.

Can Indians buy Ardelyx shares?

Yes, Indians can invest in the Ardelyx (ARDX) from India.

With INDmoney, you can buy Ardelyx at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ardelyx at zero transaction cost.

How can I buy Ardelyx shares from India?

It is very easy to buy Ardelyx from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ardelyx be purchased?

Yes, you can buy fractional shares of Ardelyx with INDmoney app.

What are the documents required to start investing in Ardelyx stocks?

To start investing in Ardelyx, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.